Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Alcon
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
ophthalmology
|
| gptkbp:founded |
2005
|
| gptkbp:founder |
gptkb:Casey_C._Kopczynski
gptkb:David_L._Epstein |
| gptkbp:headquartersLocation |
gptkb:Durham,_North_Carolina,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aerie Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Rhopressa
gptkb:Rocklatan |
| gptkbp:numberOfEmployees |
approximately 300 (2022)
|
| gptkbp:primaryTherapeuticArea |
glaucoma
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AERI
|
| gptkbp:website |
https://www.aeriepharma.com/
|
| gptkbp:bfsParent |
gptkb:Sofinnova_Investments
|
| gptkbp:bfsLayer |
6
|